Search This Blog

Tuesday, July 7, 2026

FDA grants accelerated approval to Vera's TRUTAKNA for proteinuria reduction

 

FDA grants accelerated approval to Vera's TRUTAKNA for proteinuria reduction in adults with primary IgA nephropathy at risk of progression

  • TRUTAKNA, marketed as atacicept-vymj, is indicated to reduce proteinuria in adult primary IgA nephropathy patients.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)